## DRAFT

ANTI-INFECTIV	<b>ES-SYSTEMIC</b>	
ANTIVIRALS		
Hepatitis C Agents		
Preferred	Non-Preferred	
Copegus® Tablet	Pegasys® Vial	
Moderiba® Dosepack (branded generic for Ribasphere® Ribapak)	Ribasphere® Ribapak	
Moderiba® Tablet (branded generic for Copegus®)	Ribasphere® Capsule / Tablet (branded generic for Rebatrol)	
Pegasys® Proclick / Syringe		
ribavirin capsule / tablet (generic for Copegus®, Rebetol®)		
Clinic	cal criteria apply	
November 1	, 2017- April 30, 2018	
	, 2017 April 20, 2010	
All genotypes without cirrhosis	Dell'interM Tehlet (for constants 2)	
Mayvret <sup>TM</sup> (8 weeks of therapy)	Daklinza <sup>™</sup> Tablet (for genotype 3) (must request Sovaldi® in addition to Daklinza® with a	
Mayvret <sup>ran</sup> (8 weeks of therapy)	separate PA)	
	Epclusa® Tablet (for genotype 1,4,5 and 6)	
All genotypes with compensated cirrhosis (Child Pugh-A)	Olysio® Capsule	
Mayvret <sup>™</sup> (12 weeks of therapy)	Sovaldi® Tablet	
Mayvret <sup>™</sup> (12 weeks of therapy)		
Mayvret <sup>™</sup> (12 weeks of therapy)	Sovaldi® Tablet	
Mayvret <sup>™</sup> (12 weeks of therapy) All genotypes with decompensated cirrhosis (Child-Pugh B and C)	Sovaldi® Tablet Technivie <sup>™</sup> Dose Pack (for genotype 4)	
	Sovaldi® Tablet   Technivie™ Dose Pack (for genotype 4)   Viekira™ Pak	
All genotypes with decompensated cirrhosis (Child-Pugh B and C)	Sovaldi® Tablet   Technivie™ Dose Pack (for genotype 4)   Viekira™ Pak   Viekira™ XR Tablet	
All genotypes with decompensated cirrhosis (Child-Pugh B and C) Epclusa® Tablet <del>(for genotype 2 and 3)-</del> in combination with ribavirin	Sovaldi® Tablet   Technivie™ Dose Pack (for genotype 4)   Viekira™ Pak   Viekira™ XR Tablet   Zepatier® Tablet	
All genotypes with decompensated cirrhosis (Child-Pugh B and C) Epclusa® Tablet <del>(for genotype 2 and 3)-</del> in combination with ribavirin All genotypes previously treated with an HCV regimen containing an NS5.	Sovaldi® Tablet   Technivie <sup>™</sup> Dose Pack (for genotype 4)   Viekira <sup>™</sup> Pak   Viekira <sup>™</sup> XR Tablet   Zepatier® Tablet	
All genotypes with decompensated cirrhosis (Child-Pugh B and C) Epclusa® Tablet (for genotype 2 and 3) in combination with ribavirin All genotypes previously treated with an HCV regimen containing an NS5/ inhibitor or genotype 1a or 3 infection and have previously been treated w	Sovaldi® Tablet   Technivie <sup>™</sup> Dose Pack (for genotype 4)   Viekira <sup>™</sup> Pak   Viekira <sup>™</sup> XR Tablet   Zepatier® Tablet	
All genotypes with decompensated cirrhosis (Child-Pugh B and C) Epclusa® Tablet <del>(for genotype 2 and 3)-</del> in combination with ribavirin All genotypes previously treated with an HCV regimen containing an NS5.	Sovaldi® Tablet   Technivie <sup>™</sup> Dose Pack (for genotype 4)   Viekira <sup>™</sup> Pak   Viekira <sup>™</sup> XR Tablet   Zepatier® Tablet	

Viekira® Pak-	
Viekira® XR Tablet	
Zepatier® Tablet	
Harvoni® Tablet (for completion of therapy initiated prior to November 1, 2017)	
Clinical crit	teria apply
5/1/2018	and after
All genotypes without cirrhosis	Daklinza <sup>TM</sup> Tablet (for genotype 3)
Mayvret <sup>TM</sup> (8 weeks of therapy)	(must request Sovaldi® in addition to Daklinza® with a
	separate PA)
	Epclusa® Tablet (for genotype 1,4,5 and 6)
All genotypes with compensated cirrhosis (Child Pugh-A)	Harvoni® Tablet
Mayvret <sup>TM</sup> (12 weeks of therapy)	Olysio® Capsule
	Sovaldi® Tablet
All genotypes with decompensated cirrhosis	Technivie <sup>™</sup> Dose Pack (for genotype 4)
Epclusa® Tablet (for genotype 2 and 3) in combination with ribavirin	Viekira <sup>™</sup> Pak
	Viekira™ XR Tablet
All genotypes previously treated with an HCV regimen containing an NS5A	Zepatier® Tablet
inhibitor or genotype 1a or 3 infection and have previously been treated with an	
HCV regimen containing sofosbuvir without an NS5A inhibitor.	
Vosevi™	
Harvoni® Tablet	
Epclusa® Tablet (for genotype 2 and 3)	
Technivie® Dose Pack (for genotype 4)	
Viekira® Pak-	
Viekira® XR Tablet	
Zepatier® Tablet	